Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.93
-0.2559-0.85%
Post-market: 29.950.0121+0.04%19:30 EDT
Volume:9K
Turnover:279.68K
Market Cap:55.97M
PE:- -
High:30.22
Open:30.22
Low:29.84
Close:30.19
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.84
T/O Rate:0.50%
Dividend:0.41
Dividend Rate:1.37%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

TIPRANKS
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Dow Jones
·
Sep 29

Pfizer Gets Tax Penalty of 12.6 Million Rupees

Reuters
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29

Hengrui Pharma and Novo Nordisk Sign Licensing Agreement for HRS-1596 Project

Stock News
·
Sep 29

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

How Investors May Respond To Pfizer (PFE) ESMO Cancer Data Showcase

Simply Wall St.
·
Sep 29